Background: Optimal prostate cancer (PCa) screening strategies will focus on men most likely to have
Introduction
Most efforts regarding prostate cancer (PCa) screening now seek to identify clinically-significant and potentially-lethal cases requiring treatment, while avoiding overdiagnosis of more indolent, lowerrisk cases eligible for active surveillance 1, 2 . Disease aggressiveness is accounted for in clinical decisionmaking with widely-used stratification schemes for risk of metastasis or death 3, 4 . Men diagnosed with intact PCa may be followed with active surveillance 5 or treated with surgery, radiotherapy, androgen deprivation therapy, or a combination thereof 3 . Understanding the age-specific incidence of modern clinical risk groups (defined below) could greatly inform effective screening strategies aimed to detect potentially-lethal, localized, PCa.
Prior studies have suggested associations between older age and both higher Gleason score 6,7 and
higher-risk disease 8 . These associations have important implications for pre-test probability for screening and diagnostic tests for clinically-significant PCa. Modern clinical risk groups (hereafter referred to as "risk groups") include a distinction between unfavorable-and favorable-intermediate-risk cancer 9 .
Unfavorable-intermediate-risk and high-risk disease have similar rates of developing distant metastases and of prostate-cancer-specific mortality 10 . This differentiation has been incorporated into clinical management 3 and staging guidelines 11 . The difference between Gleason 4+3 and 3+4 is also included in modern guidelines 3, [9] [10] [11] , but age associations have not been reported for this distinction. Additionally, agespecific incidence rates (ASIRs) for PCa are unknown for risk groups in current use.
Here, we used Norwegian population data to assess associations between age and PCa risk groups. We also estimated ASIRs in Norway for each risk group. Using modern strata for Gleason score and clinical risk group, we hypothesized that older men are more likely to have more advanced PCa.
Methods

Patient Population
We identified all men with PCa diagnosed from 2014-2017 from the Cancer Registry of Norway.
Overall, the registry has been reported to have over 99% validity and completeness for PCa reporting 12, 13 . 10 . PCa remains a leading public health problem-worldwide, it is the second most common malignancy diagnosed in men and a leading cause of cancer mortality 23, 24 .
The major PCa screening trials may have underestimated the potential mortality benefit of screening by including large numbers of men under 60, who had a long life-expectancy but a relatively low incidence of unfavorable-intermediate-risk or high-risk disease 16, 25 . In fact, a large European trial showed a mortality benefit to screening, but on subset analysis, there was no significant benefit in men under age 65 26 . Too much focus on screening younger men (barring other risk factors) will likely tend to lead to higher relative rates of false positives and of overdiagnosis of low-risk cancer. Meanwhile, early treatment of intermediate-risk or high-risk disease could reduce PCa morbidity and mortality 5, [27] [28] [29] . The present study suggests that healthy older men-those with a reasonably long life-expectancy-may be among those most likely to benefit from screening, as they are at greater risk of aggressive PCa that can cause morbidity and/or mortality if left untreated.
Our findings are consistent with prior data suggesting associations between increased age and worse PCa Gleason scores and risk groups [6] [7] [8] 30 . We show these associations hold true for modern Gleason score and risk-stratification schemes. Additionally, previous work has reported population PCa stagespecific incidence rates and trends over eras in time, mainly by dividing cases into localized, regional, or distant disease 31, 32 , or by using strict definitions of TNM staging 33 . The introduction of opportunistic PSA screening in Norway led to increased incidence rates of localized and regional PCa in younger men over time 31 , but no subdivision was made for localized disease that was potentially-lethal versus eligible for There are also continued increases in absolute rates of regional and metastatic disease in men as they age;
this is an expected finding as older men are less likely to be screened for PCa 4 . Older men may also be more likely to present with metastatic disease because they were already at increased risk of having a potentially-lethal cancer, making them more prone to metastases 10 . Altogether, screening for PCa in healthy, older men (say, between 70-75 years) may allow for improved risk-stratification efforts, leading to the identification of disease while it remains potentially curable. Age could certainly be combined with other risk factors to further optimize screening strategies 1, [34] [35] [36] [37] .
Notably, Norway opted not to participate in the major European PCa screening trial 16 considering the advisability and timing of possible screening (with a focus on detecting potentially-lethal disease). Knowing that older, healthy men are at the greatest risk of being diagnosed with a potentiallylethal, but potentially-curable PCa may aid physician decision-making when determining who may receive the most benefits from screening. Strategies to detect potentially-lethal disease will be most effective when the pre-test probability is high-i.e., when the underlying prevalence of clinicallysignificant disease is high-hence, the need to be guided by epidemiological patterns like those presented here.
Our work has limitations. We could not separate out very-low or very-high-risk cases, as PSA density information and Gleason score for each biopsy core are not registered in the Cancer Registry of Norway. These cases tend to be clinically managed similarly to low and high-risk PCa, respectively, and thus were combined with those categories 3 . Approximately 30% of the cohort could not be assigned a precise risk group due to incomplete PSA or clinical T stage information; most of these had partial data available for Gleason score and clinically-significant PCa analyses. Finally, while we obtained plausible estimates of age-specific incidence and proportion for an entire population using high-quality registry data, the direct findings are limited to Norway. Nevertheless, the patterns observed here could be similar in other western countries, a suggestion that is partially supported by prior work in the USA 6, 8 .
Conclusions
Both the proportion and absolute incidence rates of clinically-significant PCa (using modern definitions) increase with age. Notably, the absolute incidence of high-risk disease at ages 75-79 is over six times higher than that at ages 55-59. Older men are also more likely to be diagnosed with higher
Gleason score. Efforts to optimize PCa screening for efficient detection of localized, potentially-lethal disease should account for this strong age dependence. Norway prostate cancer age-specific incidence rates (per 100,000 males) by clinical risk group stratification. Intermediate-risk prostate cancer is subdivided into favorable and unfavorable risk. 
